PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor

Anticancer Research

Volumn 33, Issue 4, 2013, Pages 1307-1316

  Nair, Jayasree S ^a   Sheikh, Tahir ^a   Ho, Alan L ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gamma secretase; Melanoma; PTEN; RO492907

Indexed keywords

N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TEMOZOLOMIDE;

ARTICLE; BREAST CELL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; WILD TYPE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; APOPTOSIS; BENZAZEPINES; BLOTTING, WESTERN; CELL AGING; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; MUTATION; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84876752938     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML and Artavanis-Tsakonas S: Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Nat Acad Scie USA 92: 6414-6418, 1995.
2. Daniel B, Rangarajan A, Mukherjee G, Vallikad E and Krishna S: The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J Gen Virol 78: 1095-1101, 1997. (Pubitemid 27207596)
3. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JF, Koontongkaew S, Liotta LA, Emmert-Buck M and Gutkind JS: Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries. Oral Oncol 36: 474-483, 2000. (Pubitemid 30645984)
4. Hendrix MJ, Seftor RE, Seftor EA, Gruman LM, Lee LM, Nickoloff BJ, Miele L, Sheriff DD and Schatteman GC: Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res 62: 665-668, 2002. (Pubitemid 34126938)
5. Tohda S and Nara N: Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk & Lymph 42: 467-472, 2001. (Pubitemid 32725602)
6. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H and Dorken B: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99: 3398-3403, 2002. (Pubitemid 34525322)
7. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, Dettke M and Berger R: Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 99: 3742-3747, 2002. (Pubitemid 34534546)
8. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999. (Pubitemid 29291335)
9. Fortini ME: Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev 3: 673-684, 2002.
10. Wu L, Sun T, Kobayashi K, Gao P and Griffin JD: Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 22: 7688-7700, 2002.
11. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R and Wheler JJ: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30: 2348-2353, 2012.
12. Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I and Hernando E: The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PloS One 6: e25264, 2011.
13. Bailey AM and Posakony JW: Suppressor of hairless directly activates transcription of enhancer of split complex genes in response to Notch receptor activity. Genes Dev 9: 2609-2622, 1995. (Pubitemid 3001579)
14. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, Miele L, Aguet M, Radtke F and Dotto GP: Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 20: 3427-3436, 2001. (Pubitemid 32634350)
15. Palomero T, Dominguez M and Ferrando AA: The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 7: 965-970, 2008. (Pubitemid 351679827)
16. Cantley LC and Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Nat Acad of Scie USA 96: 4240-4245, 1999. (Pubitemid 29190320)
17. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998. (Pubitemid 28458022)
18. Tse AN and Schwartz GK: Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Can Res 64: 6635-6644, 2004. (Pubitemid 39297924)
19. Motwani M, Delohery TM and Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Can Res 5: 1876-1883, 1999. (Pubitemid 29334472)
20. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ and Miele L: Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Can Res 68: 5226-5235, 2008.
21. De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R and Hunter DJ: Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet 37: 336-341, 2000. (Pubitemid 30261264)
22. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997. (Pubitemid 27148818)
23. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J and Rosen N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Can Cell 8: 287-297, 2005. (Pubitemid 41443414)
24. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB and Schwartz GK: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Can Res 69: 573-582, 2009.
25. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL and Klisovic RB: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 108: 3674-3681, 2006. (Pubitemid 44864544)
26. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A and Solit DB: Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31: 446-457, 2012.
27. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L and Garraway LA: Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485: 502-506, 2012.
28. Krop I, Demuth T, Guthrie T, Wen P Y, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R and Lorusso P: Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Onc 30: 2307-2313, 2012.
29. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K and Hendrix MJ: A molecular role for lysyl oxidase in breast cancer invasion. Can Res 62: 4478-4483, 2002. (Pubitemid 34827311)
30. Blackman SC, Klappenbach JA, Railkar RA, Tanis K, Podtelezhnikov A, Loboda A, Dai X, Hing J, Stone J, Harman A, Hardwick J, Iannone R and Bergstrom D: Identification of a time- and dose-responsive transcriptional signature of Notch pathway inhibition in plucked human hair follicles following exposure to the gamma-secretase inhibitor MK-0752 (Abstract B41). Mol Can Ther 8: 2009.